Full-Time
Associate Director
Multiple Teams
Posted on 9/12/2026
Mirum Pharmaceuticals
201-500 employees
ASBT inhibitors for rare liver diseases
No salary listed
Remote in USA
Remote
Must live near a major airport; approximately 65% domestic travel is required.
Bachelor's
 Growth & Marketing (1) |
|---|
Get referred to Mirum Pharmaceuticals
See people who can refer or advise you
- A bachelor's degree is required.
- At least 6 years of pharmaceutical or related industry experience, mostly in a customer-facing capacity, is required.
- Ability to think strategically and work hands-on to deliver on multiple priorities.
- Ability to draw insights from varied sources and understand markets and competition.
- Ability to compile relevant data and perform analysis.
- Ability to synthesize complex and diverse information and recognize trends and interrelationships.
- Ability to meet objectives and deadlines, promote efficiency and effectiveness, and incorporate improvements and program return on investment.
- Strong project management experience and ability to manage and coordinate projects with multiple internal stakeholders and vendors on time.
- Excellent verbal, written, organizational, and interpersonal skills are required.
- Proficiency with Microsoft Office tools, including Word, PowerPoint, and Outlook.
- Must live near a major airport and be able to travel regularly throughout the assigned area and attend meetings at Mirum offices and off-site locations throughout the United States.
- Develop and communicate the strategic vision and operational plan for engaging key opinion leaders.
- Develop and oversee the development and execution of individual key opinion leader mapping plans.
- Partner closely with the Director of Marketing for the Genetics, Endocrinology, and Metabolics brands.
- Build and maintain productive, collaborative, and compliant relationships with peers leading teams in Marketing, Market Access, Patient Services, and Medical Affairs.
- Work closely with the Field Sales team on the execution of thought-leader initiatives and programs.
- Build mechanisms to collect, synthesize, integrate, and communicate insights to the brand to inform tactics.
- Ensure compliant, value-added connections between thought leaders and Mirum across the organization.
- Collaborate with Medical Leadership on engagement strategy and planning, including support and coordination of commercial advisory boards.
- Engage with key opinion leaders to solicit feedback that shapes and informs brand strategy.
- Contribute to marketing strategy for conferences and congresses, including sponsorships, communication and messaging, and advocacy-group engagement.
- Partner with marketing portfolio leaders and field leadership to develop appropriate key performance indicators and metrics supporting brand marketing and execution goals.
- Act as the primary field contact for maintaining two-way dialogue on key opinion leader engagement, potential speaker identification, and emerging thought leaders and experts.
- Analyze market data, confirm data reliability, and inform team stakeholders to support informed decisions.
- Engage Legal and Compliance partners to ensure programs and processes meet high ethical standards.
- At least 3 years of experience working with Genetics and/or Endocrinology key opinion leaders.
- At least 2 years of experience working in a cross-collaborative, matrix environment.
- Healthcare providers, including genetic counselors or advanced practice providers, with 3–5 years of experience in genetics and/or endocrinology will also be considered.
Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases. Its lead drug LIVMARLI (maralixibat) is an oral ASBT inhibitor that lowers bile acid buildup to relieve itching in cholestatic conditions such as Alagille syndrome, and the company is pursuing LIVMARLI for additional rare liver diseases, with volixibat as another ASBT inhibitor in its pipeline. The company differentiates itself by focusing on rare pediatric and adult cholestatic diseases and building dedicated commercialization infrastructure in the U.S. and other major markets, including partnerships with physicians, payers, and patient groups to improve patient access. Mirum’s goal is to bring effective therapies to patients with rare bile-duct and liver disorders, expand LIVMARLI indications, and establish a sustainable market presence in key markets.
Company Size
201-500
Company Stage
IPO
Headquarters
Foster City, California
Founded
2018
Get referred to Mirum Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 net product sales reached $176.2 million, and guidance rose to $700 million.
- Rob Myers starts September 21, 2026, strengthening hepatology leadership before key readouts.
- Volixibat, brelovitug, and zilurgisertib create multiple catalysts through first-half 2027.
What critics are saying
- FDA recommended another volixibat Phase 3 on August 5, 2026, delaying PSC filing.
- If LIVMARLI growth slows, Mirum loses the cash engine funding its pipeline.
- Zilurgisertib’s September 26, 2026 PDUFA denial would crush sentiment and financing flexibility.
What makes Mirum Pharmaceuticals unique
- LIVMARLI dominates rare pediatric cholestatic disease with expanding PFIC and biliary atresia labels.
- Mirum combines commercialization strength with late-stage hepatology pipeline breadth across PSC, HDV, and FOP.
- Exclusive zilurgisertib rights from Incyte add a near-term rare-disease launch platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↑ 0%Mirum Pharmaceuticals has appointed Dr Rob Myers as chief medical officer, effective 21 September 2026. Dr Myers will lead the company's global medical and clinical development functions. Dr Myers brings over 20 years of experience in drug development, with particular expertise in hepatology. He joins from OrsoBio, where he served as chief medical officer and head of development. Previously, he held senior leadership positions at Gilead Sciences, overseeing clinical development programmes across liver fibrosis, cholestatic liver diseases, and gastrointestinal inflammation. Dr Myers has published more than 200 peer-reviewed papers and has contributed to advancing understanding of primary sclerosing cholangitis. He holds an MD from Western University and a master's degree in epidemiology from the University of Calgary.
US FDA approves Regeneron's rare bone disorder drug. Regeneron's Pasatru has received US FDA approval for adults with FOP after clinical trials showed a significant reduction in abnormal bone formation. By Reuters August 20, 2026, 8:59:40 AM IST (Published) The US FDA on Wednesday (August 19) approved Regeneron's drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues. New York-based Regeneron's shares rose 4%. The drug, garetosmab, branded as Pasatru, was approved to treat adults with fibrodysplasia ossificans progressiva (FOP) - a condition in which muscle, tendon and ligament tissue gradually turns into bone, leading to a "second skeleton" that causes progressive loss of mobility and reduced life expectancy. In a 56-week trial involving 63 participants, Pasatru reduced the development of new bone abnormalities by 94% in patients treated with a 3 mg per kg dose and by 90% in those given a 10 mg per kg dose, compared with a placebo. The drug works by blocking Activin A, a protein involved in triggering abnormal bone growth in patients with FOP. Susan Rhee, a member of Regeneron's clinical team, told Reuters last week that the company plans to start a trial for children later this year. The drug will compete with French drugmaker Ipsen's oral treatment Sohonos, which in 2023 became the only other treatment approved by the US Food and Drug Administration. Incyte and partner Mirum Pharma, as well as privately held Ashibio, are also developing treatments for the condition. In 2020, Regeneron paused dosing in a mid-stage trial of the drug after five patient deaths, ultimately discontinuing the study and working with global regulators to design the late-stage trial, according to the company. The condition affects roughly 1 in 2 million people worldwide, with around 800 to 900 active diagnosed cases globally, according to data from the National Institutes of Health.
Mirum Pharmaceuticals shares plunged 15% on Thursday after the FDA recommended an additional Phase 3 study for its liver disease candidate Volixibat, potentially delaying the new drug application until the first half of 2027. Citizens lowered its price target to $137 from $146 whilst maintaining an Outperform rating. The regulatory setback overshadowed strong second-quarter results. Mirum reported revenue of $176.2 million, beating analysts' estimates of $167.3 million. The company raised its full-year net product sales guidance to $680 million to $700 million, from $660 million to $680 million. Mirum ended the quarter with $561.3 million in cash and equivalents. Volixibat has already received FDA Breakthrough Therapy and Orphan Drug designations.
Mirum Pharmaceuticals raised its full-year 2026 net product sales guidance to $680 million to $700 million, citing growth in Alagille syndrome and expanding adult PFIC diagnosis. The company secured $690 million through a convertible note offering, improving its capital structure whilst settling 75% of 2029 notes. The firm identified a significant opportunity in adult PFIC, estimating at least 2,000 addressable patients each in the US and Europe. Commercial operations achieved a high-50s percent cash contribution margin, representing a 5 percentage point year-over-year improvement. Mirum delayed its volixibat PSC NDA submission due to alignment issues with FDA reviewers but received Breakthrough Therapy Designation. The company targets a first-half 2027 NDA submission for PSC and anticipates Phase III PBC results in Q1 2027.
Mirum Pharmaceuticals reported revenue of $176.24 million for the quarter ended June 2026, up 37.9% year-over-year. The figure exceeded the consensus estimate of $164.76 million by 6.97%. The company posted a loss of $0.80 per share, compared to $0.12 a year ago, slightly missing the estimated loss of $0.77 per share. Product sales showed strong performance across categories. Livmarli generated $128.72 million, surpassing the $119.6 million analyst estimate. Bile acid medicines brought in $47.52 million, also beating expectations of $45.64 million. Despite beating revenue estimates, Mirum's shares fell 18.7% over the past month, underperforming the S&P 500's 3.5% gain.